HomeCompareJAXAF vs ABBV

JAXAF vs ABBV: Dividend Comparison 2026

JAXAF yields 5000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JAXAF wins by $566.48M in total portfolio value
10 years
JAXAF
JAXAF
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$566.59M
Annual income
$13,723,006.45
Full JAXAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JAXAF vs ABBV

📍 JAXAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJAXAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JAXAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JAXAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JAXAF
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$11,664,555.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, JAXAF beats the other by $11,643,499.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JAXAF + ABBV for your $10,000?

JAXAF: 50%ABBV: 50%
100% ABBV50/50100% JAXAF
Portfolio after 10yr
$283.34M
Annual income
$6,873,889.10/yr
Blended yield
2.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JAXAF
No analyst data
Altman Z
-0.4
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JAXAF buys
0
ABBV buys
0
No recent congressional trades found for JAXAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJAXAFABBV
Forward yield5000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$566.59M$102.3K
Annual income after 10y$13,723,006.45$24,771.77
Total dividends collected$431.41M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JAXAF vs ABBV ($10,000, DRIP)

YearJAXAF PortfolioJAXAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$260,700$250,000.00$11,550$430.00+$249.2KJAXAF
2$3,324,510$3,045,560.75$13,472$627.96+$3.31MJAXAF
3$21,705,698$18,148,472.29$15,906$926.08+$21.69MJAXAF
4$78,594,831$55,369,734.26$19,071$1,382.55+$78.58MJAXAF
5$177,783,375$93,686,906.45$23,302$2,095.81+$177.76MJAXAF
6$289,257,188$99,028,976.26$29,150$3,237.93+$289.23MJAXAF
7$384,795,925$75,290,733.55$37,536$5,121.41+$384.76MJAXAF
8$458,534,679$46,803,039.60$50,079$8,338.38+$458.48MJAXAF
9$516,693,763$26,061,656.05$69,753$14,065.80+$516.62MJAXAF
10$566,585,332$13,723,006.45$102,337$24,771.77+$566.48MJAXAF

JAXAF vs ABBV: Complete Analysis 2026

JAXAFStock

Vinyl Group Ltd, together with its subsidiaries, operates as a music company in Australia. The company operates an online platform to hold official music metadata and to develop a repository of music-related information. Jaxsta Limited was founded in 2015 and is headquartered in Sydney, Australia.

Full JAXAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JAXAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JAXAF vs SCHDJAXAF vs JEPIJAXAF vs OJAXAF vs KOJAXAF vs MAINJAXAF vs JNJJAXAF vs MRKJAXAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.